Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Non-Current Assets (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Non-Current Assets for 15 consecutive years, with $45.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 13.94% to $45.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $45.8 million, a 13.94% decrease, with the full-year FY2025 number at $45.0 million, down 19.94% from a year prior.
  • Non-Current Assets was $45.8 million for Q4 2025 at Aytu Biopharma, up from $43.9 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $160.4 million in Q2 2021 to a low of $43.9 million in Q3 2025.
  • A 5-year average of $74.5 million and a median of $62.3 million in 2023 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: surged 106.03% in 2021, then crashed 51.57% in 2022.
  • Aytu Biopharma's Non-Current Assets stood at $136.3 million in 2021, then tumbled by 48.03% to $70.8 million in 2022, then fell by 15.46% to $59.9 million in 2023, then fell by 11.2% to $53.2 million in 2024, then fell by 13.94% to $45.8 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Non-Current Assets are $45.8 million (Q4 2025), $43.9 million (Q3 2025), and $45.0 million (Q2 2025).